Sentry Data Systems announces industry research results: More than half of hospital executives recognize analytics as crucial to mitigating drug diversion risks

56% see resulting need for more pharmacy analytics

Sentry Data Systems, Inc., a leader in 340B compliance and advanced healthcare analytics solutions, recently announced the results of its first annual Customer Experience Management Research study, conducted by Porter Research, an independent healthcare-focused research firm.

The primary objectives of the study included gaining insights into the most urgent concerns of Sentry’s clients and identifying their top management and compliance priorities for the next two to three years. The surveys were conducted between May and June, 2017.

78% of respondents answered “yes” when asked, “Are you aware the Federal DEA agency has created a task force seeking to identify diversion fraud in hospitals today…and there are penalties in the millions of dollars as well as prison sentences for potential violators?” And 56% said “yes” when asked, “Would knowing about the DEA Drug Diversion Task Force affect your opinion about the importance of Sentry’s analytic capabilities to identify diversion in your system?”

“As evidenced by the response numbers, drug diversion presents a major risk for hospitals today and Sentry is uniquely positioned to help our customers proactively mitigate this potentially devastating threat,” said Travis Leonardi, CEO of Sentry Data Systems. “We apply Comparative Rapid Cycle Analytics™ to identify variances in the data, including patterns in the transaction history, and pinpoint specific areas where hospitals might be out of compliance with drug diversion regulations.”

Sentry has been building its Comparative Rapid Cycle Analytics™ capabilities and Patient Data Intelligence Platform™ for the past 14 years to deliver real-world insights based on real-world data, and recently created Senturion Services — a robust team of some of the industry’s most experienced and credentialed pharmacy experts, clinicians, data scientists, and business analysts — to enable its customers to significantly improve quality of care and compliance while dramatically decreasing costs.

“Porter Research is proud to work with such an industry-leading company as Sentry Data Systems. The insights we uncovered were significant and truly resonated with the pharmacy executives we interviewed. I’m impressed with Sentry’s commitment to understanding and acting upon the voice of their customers on such impactful issues as drug diversion,” said Cynthia Porter, president of Porter Research.

About Sentry Data Systems, Inc.

Located in Deerfield Beach, FL, Sentry Data Systems, a pioneer in automated pharmacy procurement, utilization management and 340B compliance, is leading the healthcare industry in turning real-time data into real-world evidence through Comparative Rapid Cycle Analytics™ to reduce total cost of care, improve quality and provide better results for all. More than 10,000 hospitals, clinics, integrated delivery networks (IDNs) and pharmacies across the country rely on Sentry’s unique proprietary data set for their analytics, decision support, procurement, drug utilization and compliance solutions. Since 2003, Sentry’s solutions have processed over 8 billion dispensations on more than 1.6 billion claims and have helped hospitals, health systems and IDNs realize more than $8.5 billion in savings to achieve their safety net mission and continue to serve their communities.

Media Contact
Brian Parrish
Vice President Marketing


Cision PR Newswire link